ADCs with ImmunoGen technology are a type of targeted anticancer therapy.

Each ADC contains a highly potent cancer-killing agent attached to an antibody that binds to a target found on tumor cells. The antibody serves to target the potent cancer-killing agent to tumor cells, which the agent can then kill.

#
#
#
#
#
#
#

ImmunoGen or Partner

Antibody that binds to a target found on tumor cells

ImmunoGen

Linker, which impacts ADC performance

ImmunoGen


Highly potent cancer-killing agent


An ADC integrated system

Cancers differ in the targets present on the tumor cells. Scientists can develop ADC compounds for different types of cancers by identifying a suitable target, creating a quality antibody and attaching an effective cancer-killing agent using an appropriate linker.


Last updated: February 10, 2016

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue